Kalderos aims to bring clarity and transparency to the complex world of drug discounts, facilitating the smooth operation of discount programs and ensuring funds flow seamlessly as intended to support safety-net providers, manufacturers, and patient access to care and treatments.

David DeVogel

Jeremy Docken

Jim Bonkowski

Kalderos

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Metric
Company Name	Kalderos	H. Lundbeck A/S
Symbol		LUN
MSH ID	COM:KALDEROS	COM:LUNDBECK
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Healthcare & Health Services	Drug Manufacturers - Specialty & Generic
Country		DK
Stage
Employee Count	51	5.35K
Website	kalderos.com	lundbeck.com
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		2.82B
Revenue (LTM)
Revenue (NTM)
Gross Profit		2.18B
EBITDA		720.26M
Operating Income		452.47M
Net Income		324.30M
EPS		0.33
Diluted EPS		0.33
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.78
Operating Profit Margin		0.17
EBITDA Margin		0.26
Net Profit Margin		0.12
Return on Equity		0.11
Return on Assets		0.07
Return on Capital Employed		0.11

KALD

COM:KALDEROS

Kalderos

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		26.03
P/B Ratio		1.88
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		1.89
EV Multiple		9.97

Metric
Days Sales Outstanding
Days Payables Outstanding		391.61
Days Inventory Outstanding		368.68
Operating Cycle		448.16
Cash Conversion Cycle		101.40
Asset Turnover		0.53

Metric
Operating Cash Flow		577.80M
Free Cash Flow		506.85M
Cash Flow to Debt		1.23
Operating Cash Flow/Sales		0.23
Free Cash Flow Yield

Metric
Cash & Equivalents		709.50M
Accounts Receivable		-23.65M
Inventory		626.94M
Goodwill		779.88M
Debt to Capitalization		0.23
Debt to Assets		0.15
Current Ratio		0.98
Quick Ratio		1.32

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue		0.23
SG&A to Revenue		0.06